Astrazeneca ADR Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Astrazeneca ADR Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | -1.350% | 4.651% | 2.273% | 30.058% | 7.656% | 41.509% | 0.559% |
| Bayer AG ADR | -1.670% | 0.855% | -2.479% | 66.197% | 34.091% | -4.839% | 3.509% |
| Novartis AG ADR | -1.450% | 1.515% | 2.290% | 22.374% | 13.080% | 44.086% | 67.920% |
News
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Key Points
- Interested in Innate Pharma S.A. Sponsored ADR? Here are five stocks we like better.
- Innate Pharma raised €30 million to fund its lacutamab, IPH4502 and preclinical ADC programs
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
In recent weeks, two pharmaceutical stocks, AstraZeneca (NYSE: AZN) and Bristol Myers Squibb (NYSE: BMY), have become the subject of merger rumors. At the start of the month, the Financial Times
Royalty Pharma Q2 Earnings Call Highlights
Key Points
- Interested in Royalty Pharma PLC? Here are five stocks we like better.
- Royalty Pharma raised its 2026 outlook for the second consecutive quarter, now forecasting portfolio receipts